Covered recipient · General Payments record
HAWK CAMBRON
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$913.93
- Reported across 58 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $277.10 | 19 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $184.03 | 13 |
| Lilly USA, LLC | $36.14 | 2 |
| Amgen Inc. | $16.16 | 1 |
| Novo Nordisk AS | $14.20 | 1 |
| GlaxoSmithKline, LLC. | $13.45 | 1 |
| Exact Sciences Corporation | $13.12 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.95 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407473 | CMS |
| ABBVIE INC. | $28.62 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407475 | CMS |
| ABBVIE INC. | $8.77 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407477 | CMS |
| ABBVIE INC. | $14.22 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407479 | CMS |
| ABBVIE INC. | $29.87 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407481 | CMS |
| ABBVIE INC. | $14.78 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407483 | CMS |
| ABBVIE INC. | $5.91 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407485 | CMS |
| ABBVIE INC. | $11.49 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407487 | CMS |
| ABBVIE INC. | $10.22 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407489 | CMS |
| ABBVIE INC. | $7.43 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407491 | CMS |
| ABBVIE INC. | $8.35 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407493 | CMS |
| ABBVIE INC. | $8.16 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407495 | CMS |
| ABBVIE INC. | $11.26 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103407497 | CMS |
| Amgen Inc. | $16.16 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117216250 | CMS |
| Exact Sciences Corporation | $13.12 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114605709 | CMS |
| GlaxoSmithKline, LLC. | $13.45 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116548367 | CMS |
| Lilly USA, LLC | $21.70 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134997130 | CMS |
| Lilly USA, LLC | $14.44 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135016146 | CMS |
| Novo Nordisk Inc | $14.20 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096937137 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.